表观遗传原始化促进了对氨酸激酶抑制剂的耐药性和基因放大
Rebecca M Starble1,2,3, Eric G Sun1,2,4, Rana Gbyli1,2
1Department of Genetics, Yale School of Medicine, New Haven, CT, USA.
Nature structural & molecular biology
|October 23, 2025
概括
瘤基因放大驱动肺腺癌 (LUAD) 中对氨酸激酶抑制剂 (TKI) 的耐药性. 一种叫做METTL7A的蛋白质重塑色素,使基因放大和TKI耐药性成为可能,提供了一个新的治疗点.
科学领域:
- 基因组学就是基因组学.
- 癌症生物学 癌症生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 基因拷贝数控制对于哺乳动物细胞功能和基因组稳定性至关重要.
- 瘤基因放大是癌症的标志,促进瘤生长和进展.
- 肺腺癌 (LUAD) 中的氨酸激酶抑制剂 (TKI) 耐药性通常涉及瘤基因放大,但机制尚不清楚.
研究的目的:
- 调查TKI抗性LUAD中瘤基因放大背后的机制.
- 在TKI耐药性获得过程中识别染色质动态的新型调节剂.
- 探索METTL7A在瘤基因放大和TKI抵抗中的作用.
主要方法:
- 在未经药物治疗和耐TCI的LUAD细胞中分析染色素特征 (CTCF,凝聚素,H3K27Ac).
- 在基因放大之前对染色质重塑事件的调查.
- 使用METTL7A枯竭的功能研究来评估其在TKI耐药性中的作用.
主要成果:
- LUADs表现出明显的染色体特征,其中CTCF和凝聚素沉积与片边界相关.
- 一种染色质原始效应,包括增加的H3K27Ac和凝聚荷载,在TKI耐药性期间先进行瘤基因放大.
- METTL7A结合放大位置,调节凝聚力招募和TAD间相互作用,对TKI耐药性至关重要.
结论:
- METTL7A具有意想不到的染色体调节功能,在复制数增加之前重新塑造景观.
- METTL7A对于获得和维持LUAD中TKI耐药性至关重要.
- 准METTL7A的染色质功能可能为克服肺癌中TKI抵抗提供了一种策略.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer-Critical Genes I: Proto-oncogenes
11.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.0K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Induced Pluripotent Stem Cells
5.3K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.3K


